Janux Therapeutics, Inc. Share Price
NASDAQ: JANX | Small CapJanux Therapeutics, Inc. Stock Performance
Open $18.68 | Prev. Close $18.77 | Circuit Range N/A |
Day Range $17.98 - $18.68 | Year Range $12.14 - $35.24 | Volume 53,516 |
Average Traded $18.22 |
Janux Therapeutics, Inc. Share Price Today
As of 31 August 2026, Janux Therapeutics, Inc.'s share price is $18.02. The stock opened at $18.68, compared to its previous close of $18.77. During today's trading session, Janux Therapeutics, Inc.'s share price traded between $17.98 and $18.68, with an average price of $18.34. Over the past 52 weeks, the stock has recorded a high of $35.24 and a low of $12.14. In terms of performance, Janux Therapeutics, Inc.'s share price has risen by 32.21% over the last six months and is down 20.65% on a year-on-year basis.
Janux Therapeutics, Inc. Share Price Chart
Janux Therapeutics, Inc. Stock Fundamentals & Key Indicators
Market Cap $1.12B | PE Ratio (TTM) -9.85 | Dividend Yield N/A |
EPS (TTM) $-1.83 | Revenue (TTM) $10.00M | Return On Equity (TTM) -11.88% |
Profit Margin -1136.25% | Debt to Equity 0.03 | Quarterly Earnings Growth YoY 13.35% |
Janux Therapeutics, Inc. Quarterly Profit & Loss
All figures in USD
Janux Therapeutics, Inc. Annual Profit & Loss
All figures in USD
About Janux Therapeutics, Inc.
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms technology to treat patients with cancer. Its clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor that is in Phase 1 clinical trial for the treatment of various solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer. Janux Therapeutics, Inc. has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. The company was incorporated in 2017 and is headquartered in San Diego, California.
Janux Therapeutics, Inc. Historical Returns
| Month | Open | Close | Change % |
|---|---|---|---|
Aug 2026 | $15.23 | $18.77 | +23.94% |
Jul 2026 | $15.36 | $15.14 | -1.30% |
Jun 2026 | $14.50 | $15.34 | +5.14% |
May 2026 | $14.20 | $14.59 | +1.60% |
Apr 2026 | $14.11 | $14.36 | +3.38% |
Mar 2026 | $13.40 | $13.89 | +1.91% |
Feb 2026 | $13.61 | $13.63 | -0.44% |
Jan 2026 | $13.75 | $13.69 | -0.80% |
Dec 2025 | $33.70 | $13.80 | -59.59% |
Nov 2025 | $28.32 | $34.15 | +18.87% |
Oct 2025 | $24.86 | $28.73 | +17.39% |
Sep 2025 | $23.09 | $24.48 | +7.77% |
JANX Share Price FAQs
What is Janux Therapeutics, Inc. share price today?
What is the 52 week high and 52 week low of Janux Therapeutics, Inc. stock?
What is JANX's market capitalisation today?
What is JANX's net income for the last quarter?
What is the 5 year returns of JANX?
What is the high & low stock price of JANX today?
Can I buy JANX shares in India?